FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. In this webinar, we discussed what these and other data meant for women, including young and adolescent girls.
After FACTS: What’s next for HIV prevention in women?
Success with PrEP: Next Steps to Support Policy Decisions in Southern and East Africa
Convened on 26 October 2014 by AVAC, UNAIDS and WHO, this meeting brought together representatives of ministries of health and national AIDS councils, PrEP researchers and participants from research and demonstration sites where PrEP is currently being delivered in Kenya, Mozambique, South Africa, Uganda and Zimbabwe, along with funders, manufacturers and HIV advocates and activists. Through a series of presentations, moderated discussions and small group work, participants shared current experiences and helped define a structured approach to considering the integration of PrEP in HIV prevention programs in the region. In addition, some of the knowledge gaps that remain to be researched were identified.
Slides from the Workshop on Alternative Trial Designs for Microbicides
CONRAD, AVAC and the Forum for Collaborative HIV Research convened a workshop on alternative trial designs for microbicides which generated lively discussion among more than 60 participants. All slide presentations from the workshop are included.
What do women want in multipurpose technologies?
Multipurpose Prevention Technologies (MPTs) are a fast-growing area in women’s sexual and reproductive health. On November 12, AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria and South Africa.
Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
The Bottom Line in HIV Prevention… Rectal Microbicides
“The Bottom Line in HIV Prevention… Rectal Microbicides” was presented by Jim Pickett at the 22nd Annual Illinois HIV/STD Conference, October 16, 2013. This presentation provides introductory information on rectal microbicides as an HIV prevention strategy.
Africa Needs Safe and Accessible Lube Today; Rectal Microbicides Tomorrow
“Africa Needs Safe and Accessible Lube Today; Rectal Microbicides Tomorrow” was presented by Cindra Feuer (AVAC) and Jim Pickett (IRMA) at the AMSHeR pre-conference at ICASA 2013 in Cape Town, South Africa. The presentation includes a discussion on the WHO prevention guidelines; and updates on PrEP and rectal microbicides.
Biomedical Prevention and Anal Sex
Cindra Feuer (AVAC) and Jim Pickett (IRMA) presented at AMSHeR’s 2-day Sexual Health and Rights Institute, which was held in December 2013 prior to ICASA 2013 in Cape Town, South Africa. The presentation included an update on biomedical ARV-based prevention and advocacy and rectal microbicide research and advocacy.
MTN-017 Trial Launch Webinar
Be the Generation Bridge and International Rectal Microbicide Advocates (IRMA) hosted a webinar to mark the launch of MTN-017, the first-ever phase II safety study of a rectal microbicide. Ross D. Cranston, MD, of the University of Pittsburgh School of Medicine and co-leader of MTN-017, presented on the trial details, followed by Jim Pickett of IRMA who presented on the community engagement activities undertaken in support of the trial.
GPP Overview Presentation
An AVAC PowerPoint presentation from February 2012 outlining basic information about the Good Participatory Practice guidelines including history of development, structure, and participatory practices.